Management of Hyperkalemia in CHF with Advanced CKD

Immediate Actions

• The American College of Cardiology recommends immediately discontinuing potassium supplementation and spironolactone, then adding a potassium binder to allow continuation of life-saving Entresto therapy 1

Preserve Guideline-Directed Medical Therapy

• The American Heart Association recommends continuing Entresto as it provides mortality benefit and has lower hyperkalemia risk than traditional RAAS inhibitors 2, 3
• The American Diabetes Association recommends continuing Jardiance as SGLT2 inhibitors reduce hyperkalemia risk by 16% and facilitate continuation of RAAS inhibitors 3, 1

Add Potassium Binder for Long-Term Management

• The European Society of Cardiology recommends initiating patiromer 8.4g once daily or sodium zirconium cyclosilicate 10g once daily, with the choice depending on the urgency of correction and patient-specific factors 1
• The American College of Cardiology recommends patiromer as it reduces hyperkalemia risk by 37% when used with high-dose RAAS inhibitors in HFrEF patients 2, 4, 3

Monitoring Protocol

• The European Journal of Heart Failure recommends checking potassium and renal function within 3-7 days after medication changes, at 1, 4, 8, and 12 weeks initially, and monthly for the first 3 months on potassium binders 1, 6

Consider Spironolactone Rechallenge Later

• The European Society of Cardiology recommends considering spironolactone rechallenge at 12.5-25mg daily or every other day if potassium normalizes with binder therapy 6

Critical Pitfalls to Avoid

• The European Heart Journal recommends never discontinuing Entresto as first-line approach, as RAAS inhibitors provide significant mortality benefit in CHF and withdrawal is associated with worse outcomes 5, 1
• The American College of Cardiology recommends avoiding sodium polystyrene sulfonate due to serious gastrointestinal adverse events, including colonic necrosis 1
• The American Heart Association recommends not using triple RAAS blockade due to excessive hyperkalemia risk 1

Volume Status Consideration

• The American Journal of Kidney Diseases recommends optimizing diuretic therapy to maintain euvolemia, which can help with potassium management 4, 1
• The Circulation journal recommends considering loop diuretic dose adjustment rather than adding thiazide diuretics given advanced CKD 7